Therapeutic vaccines for the treatment of HIV-1 infection

Clinical and Applied Immunology Reviews

Volumn 1, Issue 2, 2000, Pages 73-87

  Adams, Elizabeth M ^a   Fox, Lawrence M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DNA VACCINE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; VACCINIA VACCINE; VIRUS RNA; ZIDOVUDINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LIFE EXPECTANCY; MORBIDITY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 0242592802     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1529-1049(00)00007-6     Document Type: Review

References (59)

1. 1 Franchini G, Hel Z, Poudyal M, Tsai W-P, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman J, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J. Therapeutic use of a recombinant attenuated pox virus vaccine in SIV-infected macaques. 7th Conference on Retroviruses and Opportunistic Infections 2000; Abstract S6.
2. 2 UNAIDS: Report on the Global HIV/AIDS Epidemic December, 1998.
3. 3 J.S Lambert J McNamara S.L Katz T Fenton M Kang T.C VanCoti R Livingston E Hawkins J Moye Jr. W Borkowsky D Johnson R Yogev A.M Duliege D Francis A Gershon D Wara N Martin M Levin G McSherry G Smith Safety and immunogenicity of HIV-1 recombinant envelope vaccines in HIV-1-infected infants and children J Acquir Immune Defic Syndr Hum Retrovirol 19 1998 451-461
4. 4 J.J Eron M.A Ashby M.F Giordano M Chernow W.M Reiter S.G Decks J.P Lavelle M.A Conant B.G Yangco P.G Pate R.A Torres R.T Mitsuyasu T Twaddell Randomized trial of MNrgp120 HIV-1vaccine in symptomless HIV-1 infection Lancet 348 1996 1547-1551
5. 5 R.R Redfield D.L Birx N Ketter E Tramont V Polonis C Davis J.F Brundage G Smith S Johnson A Fowler phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection N Engl J Med 324 1991 1677-1684
6. 6 Schooley RT, Spino C, Chiu S, DeGruttola V, Kuritzkes DR for the ACTG 209 and ACTG 214 Study Teams. Poor immunogenicity of HIV-1 envelope vaccines with alum or MF59 adjuvant in HIV-infected individuals: Results of two randomized trials. 4th Conference on Retroviruses and Opportunistic Infections 1997; Abstract 756.
7. 7 J.A Bartlett S.S Wasserman C.B Hicks R.T Dodge K.J Weinhold C.O Tacket N Ketter A.E Wittek T.J Palker B.F Haynes Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen AIDS 12 1998 1291-1300
8. 8 R Tubiana E Gomard H Fleury M.L Gougeon B Mouthon H Picolet C Katlama Vaccine therapy in early HIV-1 infection using a recombinant Canarypox virus expressing gp160MN (ALVAC-HIV) a double-blind controlled randomized study of safety and immunogenicity AIDS 11 1997 819-820
9. 9 G Ferrari C Berend J Ottinger R Dodge J Bartlett J Toso M Moody J Tartaglia W.I Cox E Paoletti K.J Weinhold Replication-defective Canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes presented in infected patients implications for antigen-specific immunotherapy Blood 90 1997 2406-2416
10. 10 E Sandstrom B Wahren Nordic VAC-04 Study Group Therapeutic immunisation with recombinant gp160 in HIV-1 infection a randomized double-blind placebo-controlled trial Lancet 353 1999 1735-1742
11. 11 R.J Trauger F Ferre A.E Daigle F.C Jensen R.B Moss S.H Mueller S.P Richieri H.B Slade D.J Carlo Effect of immunization with inactivated gp 120-depleted Human Immunodeficiency Virus Type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA and percentage of CD4 cells J Infect Dis 169 1994 1256-1264
12. 12 Kahn J, Lagakos S, Mayer K, Murray H. A randomized, placebo-controlled multicenter study of Remune in subjects with 300-550 CD4 cells and unrestricted antiretroviral treatments. 39th ICCAC 1999; Abstract LB21.
13. 13 Valentine F, De Gruttola V, and the Remune 816 Study Team. Immunological and virological evaluations of the effects of HAART compared to HAART plus an inactivated HIV immunogen after 32 weeks. 6th Conference on Retroviruses and Opportunistic Infections 1999; Abstract 346.
14. 14 Navarro J, Abad ML, Resino S, Jimenez JL, Canto C, Carbone J, Lopez F, Esteban MA, Munoz-Fernandez MA, Fernandez-Cruz E. Augmentation of HIV-1-specific cytotoxic T lymphocytes and cellular immune responses in HIV-1 + individuals treated with a therapeutic vaccine plus antiretrovirals in a Phase II study: Two year results. XIIIth International AIDS Conference 2000; Abstract WeOrB539.
15. 15 R.A Koup J.T Safrit Y Cao C.A Andrews G McLeod W Borowsky C Farthing D Ho Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 68 1994 4650-4655
16. 16 G Pantaleo A.S Fauci New concepts in the immunopathogenesis of HIV infection Ann Rev Immunol 13 1995 487-512
17. 17 G Pantaleo C Graziosi J.F Demarest O.J Cohen M Vaccarezza K Gantt C Muro-Cacho A.S Fauci Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection Immunol Rev 140 1994 105-130
18. 18 R.J De Boer A.S Perelson Target cell limited and immune control models of HIV infection a comparison J Theoretical Biol 190 1998 201-214
19. 19 M.P D'Souza V.A Harden Chemokines and HIV-1 second receptors Nature Med 2 1996 1293-1300
20. 20 R Liu W.A Paxton S Choe D Ceradini S.R Martin R Horuk M.E MacDonald H Stuhlmann R.A Koup N.R Landau Homozygous defect in HIV-1 co receptor accounts for resistance of some multiply exposed individuals to HIV-1 infection Cell 86 1996 367-377
21. 21 M Samson F Libert B.J Doranz J Rucker C Liesnard C.M Farber S Saragosti C Lapoumeroulie J Cognaux C Forceille G Muyldermans C Verhofstede G Burtonboy M Georges T Imai S Rana Y Yi R.J Smyth R.G Collman R.W Doms G Vassart M Parmentier Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene Nature 382 1996 722-725
22. 22 M Dean M Carrington C Winkler G.A Huttley M.W Smith R Allikmets J.J Goedert S.P Buchbinder E Vittinghoff E Gomperts S Donfield D Vlahov R Kaslow A Saah C Rinaldo R Detels S.J O'Brien Genetic restriction of HIV-1 infection and progression to AIDS by a detection allele of the CXR5 structural gene Science 273 1996 1856-1862
23. 23 Rowland-Jones SL, McMichael A. Immune response in HIV-exposed seronegatives: Have they repelled the virus? Curr Opin Immunol 1995:448-455.
24. 24 G.M Shearer M Clerici Protective immunity against HIV infection has nature done the experiment for us? Immunol Today 17 1996 21-24
25. 25 Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/ fusin and blocks HIV-1 entry. Nature 196;382:829-833.
26. 26 E Oberlin A Amara F Bachelerie C Bessia J.L Virelizier F Arenzana-Seisdedos O Schwartz J.M Heard I Clark-Lewis D.F Legler M Loetscher M Baggiolini B Moser The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T cell line-adapted HIV-1 Nature 382 1996 833-835
27. 27 C.E Mackewicz L.C Yang J.D Lifson J.A Levy Non-cytolytic CD 8 T-cell anti-HIV responses in primary HIV-1 infection Lancet 344 1994 1671-1673
28. 28 P Borrow H Lewicki B.H Hahn G.M Shaw M.B Oldstone Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J Virol 68 1994 6103-6110
29. 29 G Pantaleo S Menzo M Vaccarezza C Graziosi O.J Cohen J.F Demarest D Montefiori J.M Orenstein C Fox L.K Shrager Studies in subjects with long-term nonprogressive human immunodeficiency virus infection N Eng J Med 332 1995 209-216
30. 30 Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associate with lack of disease in HIV-infected long-term nonprogressors. J Virol 1995:5838-5842.
31. 31 G.M Shearer M Clerici Type 1 and type 2 responses in HIV infection and exposure S Gupta Immunology of HIV Infection 1996 Plenum Press New York 229-241
32. 32 E.S Rosenberg J.M Billingsley A.M Caliendo S.L Boswell P.E Sax S.A Kalams B.D Walker Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia Science 278 1997 1447-1450
33. 33 B Autran G Carcelain T.S Li C Blanc D Mathez R Tubiana C Katlama P Debre J Leibowitch Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease Science 277 1997 112-116
34. 34 T.S Li R Tubiana C Katlama V Calvez H.A Mohand B Autrin Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV disease Lancet 351 1998 1682-1686
35. 35 C.J Pitcher C Quittner D.M Peterson M Connors R.A Koup V.C Maino L.J Picker HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection but decline with prolonged viral suppression Nature Med 5 1999 518-525
36. 36 M.M Lederman E Connick A Landay D.R Kuritzkes J Spritzler M St Clair B.L Kotzin L Fox M.H Chiozzi J.M Leonard F Rousseau M Wade J.D Roc A Martinez H Kossler Immunologic responses associated with 12 weeks of combined antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir Results of AIDS clinical trials group protocol 315 J Infect Dis 178 1998 70-79
37. 37 F.J Palella K.M Delaney A.C Moorman M.O Loveless J Fuhrer G.A Satten D.J Aschman S.D Holmberg Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Eng J Med 338 1998 853-860
38. 38 N.G Pakker D.W Notermans R.J De Boer M.T Roos F de Wolf A Hill J.M Leonard S.A Damier F Miedema P.T Schellekens Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection a composite of redistribution and proliferation Nature Med 4 1998 208-214
39. 39 M Hellerstein M.B Hanley D Cesar S Siler C Papageorgopoulos E Wieder D Schmidt R Hoh R Neese D Macallan S Deeks J.M McCune Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans Nature Med 5 1999 83-89
40. 40 E Connick M.M Lederman B.L Kotzin J Spritzler D.R Kuritzkes M St Clair A.D Sevin L Fox M.H Chiozzi J.M Leonard F Rousseau J D'Arc Roe A Martinez H Kessler A Landay Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response J Infect Dis 181 2000 358-363
41. 41 B.R Cullen HIV-1 auxiliary proteins making connections in a dying cell Cell 93 1998 685-692
42. 42 A Cafaro A Caputo C Fracasso M.T Maggiorella D Goletti S Baroncelli M Pace L Sernicola M.L Koanga-Mogtomo M Betti A Borsetti R Belli L Akerblom F Corrias S Butto J Heeney P Verani F Titti B Ensoli Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine Nature Med 5 1998 643-650
43. 43 D Zagury A Lachgar V Chams L.S Fall J Bernard J.F Zagury B Bizzini A Gringeri E Santagostino J Rappaport M Feldman A Burny R.C Gallo Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS Proc Natl Acad Sci USA 95 1998 3851-3856
44. 44 R Carlota B Bratt S Nordlund Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients Lancet 178 1998 92-100
45. 45 Jin X, Bauer D, Binely J, Chen D, Rammanthan M, Barsoum S, Schiller D, Hurley A, He T, El Habib R, Limabch K, Zhang L, Ho D, Markowitz M. Safety and immunogenicity study on vCP1452/gp160 vaccine in patients treated with HAART for over two years. 7th Conference on Retroviruses and Opportunistic Infections 2000; Abstract 346.
46. 46 T Hanke A McMichael Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS Immunol Lett 66 1999 177-181
47. 47 J Tartaglia J.-L Excler R El Habib K Limbach B Meigneir S Plotkin S Klein Canarypox virus-based vaccines prime-boost strategies to induce cell-mediated and humoral immunity AIDS Res Hum Ret 14 1998 S291-S298
48. 48 P Pushko M Parker G.V Ludwig N.L Davis R.E Johnston J.F Smith Replicon-helper systems from attenuated Venezuelan equine encephalitis virus expression of heterologous genes and immunization against heterologous pathogens Virology 239 1997 389-401
49. 49 S.C Gilbert J Schneider M Plebanski C.M Hannan T.J Blanchard G.L Smith A.V Hill Ty virus-like particles, DNA vaccines and modified vaccinia virus ankara comparisons and combinations Biol Chem 380 1999 299-303
50. 50 J.J Kim V Ayavoo M.L Bagarazzi M.A Chattergoon K Dang B Wang J.D Boyer D.B Weiner In vivo engineering of a cellular immune response by co administration of IL-12 expression vector with a DNA immunogen J Immunol 158 1997 816-826
51. 51 M.C Tellier R Pu D Pollock J Tartaglia E Paoletti J.K Yamamoto Efficacy evaluation of prime/boost protocol canarypoxvirus (ALVAC)-based FIV vaccine and inactivated FIV-cell vaccine against heterologous FIV challenge in cats AIDS 12 1998 11-18
52. 52 Golding B, Eller N, Inman J, Golding H, Scott DE. Development of an immunotherapeutic vaccine strategy to bypass the T-helper cell defect in HIV-1 infected persons and generate systemic and mucousal immune responses. HIV Vaccine Development: Opportunities and challenges, A Keystone Symposium 1999; Abstract 307.
53. 53 G.M Shearer L.A Pinto M Clerici Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS Immunology 20 1999 66-71
54. 54 S.K Kundu E Engleman C Benike M.H Shapero M Dupuis W van Schooten M Eibl T.C Merrigan A pilot clinical trial of HIV antigen pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients AIDS Res Hum Retro 14 1998 551-560
55. 55 M.V Dhodapkar J Krasovsky R.M Steinman N Bhardwaj Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes J Clin Invest. 105 2000 R9-R14
56. 56 Staszewski S, Phillips A, Miller V, Sabin CA, Carlebach A, Brodt R, Berger A, Hill A. Virological response to protease inhibitors in an HIV clinic cohort. 12th World AIDS Conference 1998; Abstract 12294.
57. 57 Zimmerli S, Paris D, Ladergerber B. Incidence and predictors of virologic failure of antiretroviral triple drug therapy in a community based cohort. 12th World AIDS Conference 1998; Abstract 22349.
58. 58 Reitner WM, Cimoch PJ, Berger DS, See DM, Vorce DE, Darmanin P, Baker B. Long-term effectiveness of HAART in a large clinical group and the role of viral resistance in treatment failure. 12th World AIDS Conference 1998; Abstract 22353.
59. 59 Fagard C, Gaillard A, Charvier A, Bland S, Sedallian A, Bru JP. Rapidity of negativation of viral load as a prognosis marker of failure in triple antiretroviral therapies. 12th World AIDS Conference 1998; Abstract 60448.